Juniper Networks Appoints New Chief Marketing Officer
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that effectively immediately, Jean English has been named Senior Vice President and Chief Marketing Officer. Ms. English will lead an award-winning global marketing organization that is highly data-driven, results-oriented, ROI-focused and plays a strategic role in Juniper’s growth.
Juniper has experienced unprecedented growth across all business verticals in recent years as customers increasingly look to cloud-delivered, AI-driven and secure solutions to power their strategic evolution toward delivering better digital experiences. Ms. English joins Juniper with a strong track record of successfully building holistic data-driven marketing strategies to scale enterprise growth and transform AI and cloud companies as they aim to enter new market segments and reinvent their brands.
“I am excited and honored to join Juniper Networks and the leadership team at this pivotal moment in the company’s growth. Juniper is reinventing networking with their game-changing AI technology that simplifies networks and delivers seamless end-user experiences. I look forward to applying my expertise in cloud, security and infrastructure to scale growth and help customers deliver network experiences that transform how people connect, work and live.”
- Jean English, SVP & Chief Marketing Officer, Juniper Networks
English brings more than 20 years of marketing leadership in the technology sector. Prior to Juniper, Ms. English served as SVP and CMO of NetApp, CMO at Palo Alto Networks, Global Vice President of Marketing for IBM Cloud and, most recently, CMO at Armis Security. Ms. English has also held international leadership roles, including CMO of IBM Asia Pacific located in Singapore.
“Jean is an exceptional marketing leader with a proven track record of delivering business results. She is a great addition to our team and will help further strengthen our position as the clear leader in experience-first networking and help scale Juniper’s next chapter of growth.”
- Manoj Leelanivas, EVP & Chief Operating Officer, Juniper Networks
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005149/en/
Contact information
Leslie Moore
Chief Communications Officer,
Juniper Networks
llmoore@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo
The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 14:51:00 EET | Press release
With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism General Assembly, TOURISE is reimagining the way that sectors interact to find opportunities where competitors become partners
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 14:39:00 EET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 14:06:00 EET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate ® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA ® in Combination with LENVIMA ® In Advanced Endometrial Carcinoma11.11.2025 14:00:00 EET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,” says Alok Sharma, Global Clinical Market Director at Promega. “We are committed to delivering reliable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom